FDA Prioritizes Review of Satralizumab for Rare Autoimmune Disease

The FDA has granted Priority Review to satralizumab (Enspryng) for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a rare autoimmune central nervous system disorder. This action could lead to the first approved disease-modifying therapy for MOGAD, with an FDA decision expected by January 10, 2027, based on positive Phase 3 study results. This development offers hope for patients with a condition currently lacking specific treatments.